Share
Title
Old versus New: New ARV Drug Classes Open Up New Therapeutic Choices For The Multiclass Resistant Patients. What Can Be Achieved?
Code
SA35
Session Type
Satellite
Track
Not applicable
Channel
Channel 3
Date Time
19 July 08:30- 09:30
Local Date Time
08:30 - 09:30 W. Europe Daylight Time
Chair:
Anton POZNIAK, Chelsea & Westminster, United Kingdom
Organizer:
Theratechnologies

The speaker faculty will discuss new therapeutic options for the treatment of heavily treatment-experienced patients with a multiclass resistant HIV-1 infection. The faculty will discuss potential combinations of those drugs to create a sustainable virological response for this patient population incorporating potential long-acting treatment strategies into clinical practice.

3 min
 Introduction
Anton POZNIAK, Chelsea & Westminster, United Kingdom
20 min
 New ARV drug classes open up therapeutic chances for multiclass resistant patients. What can be achieved?
Jürgen ROCKSTROH, University of Bonn, Germany
20 min
 New drugs for multiclass resistant patients, point of view of the virologist
Charlotte CHARPENTIER, France
17 min
 Discussions and Questions
Anton POZNIAK, Chelsea & Westminster, United Kingdom
Charlotte CHARPENTIER, France
Jürgen ROCKSTROH, University of Bonn, Germany